WO2026013265 - NOVEL DIPEPTIDE ACYLATING AGENTS
National phase entry is expected:
Publication Number
WO/2026/013265
Publication Date
15.01.2026
International Application No.
PCT/EP2025/069911
International Filing Date
11.07.2025
Title **
[English]
NOVEL DIPEPTIDE ACYLATING AGENTS
[French]
NOUVEAUX AGENTS D'ACYLATION DIPEPTIDIQUES
Applicants **
NOVO NORDISK A/S
Inventors
JENSEN, Kim, Birkebæk
MIKKELSEN, Jesper, Hyldal
Priority Data
24188423.8
12.07.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2655 | |
| EPO | Filing, Examination, Granting | 11046 | |
| Japan | Filing, Examination, Granting | 2183 | |
| South Korea | Filing, Examination, Granting | 2133 | |
| USA | Filing, Examination, Granting | 7590 |
Total:
25,607
Contact Us
Abstract[English]
Described are activated esters and oxazolone derivatives comprising the non-canonical amino acid, Aib; methods of making such compounds and methods of using such compounds in a process of making a target peptide comprising Aib. In addition, also the use of an activated dipeptide in a coupling reaction to obtain a target peptide, wherein the activated dipeptide comprises Aib, is described.[French]
L'invention concerne des esters et des dérivés oxazolone activés comprenant l'acide aminé non canonique, Aib; des procédés de fabrication de tels composés et des procédés d'utilisation de tels composés dans un procédé de fabrication d'un peptide cible comprenant Aib. De plus, l'invention concerne également l'utilisation d'un dipeptide activé dans une réaction de couplage pour obtenir un peptide cible, le dipeptide activé comprenant Aib.